Back to Newsroom

Puma Biotechnology Closes $138 Million Public Offering of Common Stock

LOS ANGELES, Calif., Feb. 14, 2014 — Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced the closing of an underwritten public offering of 1,126,530 shares of its common stock at a price to the public of $122.50 per share. The shares of common stock issued in the offering included 146,938 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. The net proceeds from the offering were approximately $129.3 million, after deducting the underwriting discount and estimated offering expenses payable by the Company.